https://www.selleckchem.com/products/erastin.html
Hepatitis B surface antigen (HBsAg) loss is an ideal goal for chronic hepatitis B patients. Antiretroviral therapy (ART) of HBV/HIV-1-coinfected patients can lead to hepatic flare (HF) caused by immune reconstitution-induced inflammatory syndrome (IRIS). Here, we investigated the impact of IRIS-HF on HBsAg loss. This was a retrospective study of 58 HBV/HIV-1-coinfected subjects who had been HBsAg-positive for ≥6 months before ART initiation and were followed for ≥1 year (median 9.9 years) after ART initiation. We examined humoral factor
Like
Comment
Share
